<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863265</url>
  </required_header>
  <id_info>
    <org_study_id>CANUSU-phyto3</org_study_id>
    <secondary_id>R01HL050420</secondary_id>
    <nct_id>NCT00863265</nct_id>
  </id_info>
  <brief_title>Phytosterols, Ezetimibe, and Cholesterol Metabolism</brief_title>
  <acronym>Phyteaux-III</acronym>
  <official_title>Regulation of Cholesterol Absorption: LDL Cholesterol Response to a Combination of Phytosterols and Ezetimibe (Phyto-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Utah State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phytosterols and ezetimibe each reduce intestinal cholesterol absorption by 30-55% but appear
      to have different mechanisms of action. The investigators' hypothesis is that phytosterols
      and ezetimibe given together will block cholesterol absorption in an additive fashion. In a
      randomized, placebo-controlled crossover trial the effects of placebo, ezetimibe treatment
      and ezetimibe plus phytosterol treatment will be measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will perform a randomized, placebo-controlled crossover feeding study in 25
      subjects with greater than ideal levels of LDL cholesterol who do not require
      anti-cholesterol drug treatment. Subjects will consume a baseline diet provided by a feeding
      center that is deficient in phytosterols for three periods of 21 days separated by 7-day
      washout periods. Treatments will be given in random order During period B placebo
      phytosterols and placebo ezetimibe will be given; during period C placebo phytosterols and
      active ezetimibe will be given; during period A active phytosterols and active ezetimibe will
      be given. Study endpoints are fecal cholesterol excretion and percent cholesterol absorption
      determined by gas chromatography/mass spectrometry and circulating LDL cholesterol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, crossover design. There are three periods of 21 days separated by two 7 day washouts. All subjects eat a controlled low-phytosterol diet for each of the three periods. During period B placebo phytosterols and placebo ezetimibe are given. During period C phytosterol placebo and active ezetimibe are given. During period A active phytosterols and active ezetimibe are given. Periods are assigned in random order as described in Arms below.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Phytosterols solutions were provided as food oil only (placebo) or food oil containing 2000 mg/day phytosterols (Phytosterols). Active and placebo ezetimibe tablets were provided by Merck.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol Excretion</measure>
    <time_frame>At the end of week 3 on each diet</time_frame>
    <description>Milligrams of fecal cholesterol and cholesterol metabolites excreted per day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Cholesterol Absorption</measure>
    <time_frame>Determined on the final 5 days of each dietary period</time_frame>
    <description>Percent of intestinal cholesterol absorbed. Intestinal cholesterol is comprised of dietary cholesterol intake and endogenous cholesterol secreted into the intestinal lumen. Cholesterol absorption is the percent of intestinal cholesterol that is taken back up into the body and excluded from fecal excretion. It is also referred to as the efficiency of intestinal cholesterol absorption.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>At the end of week 3 on each diet</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Crossover order ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The order of treatments is A (phytosterols + ezetimibe), B (double placebo), and C (active ezetimibe and phytosterol placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover order BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The order of treatments is B (double placebo), C (active ezetimibe and phytosterol placebo), and A (phytosterols + ezetimibe).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover order BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The order of treatments is B (double placebo), A (phytosterols + ezetimibe), and C (active ezetimibe and phytosterol placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover order ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The order of treatments is A (phytosterols + ezetimibe), C (active ezetimibe and placebo phytosterols, and B (double placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover order CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The order of treatments is C (active ezetimibe and placebo phytosterols), A (phytosterols + ezetimibe), and B (double placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover order CBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The order of treatments is C (active ezetimibe and placebo phytosterols), B (double placebo), and A (phytosterols and ezetimibe).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.</description>
    <arm_group_label>Crossover order ABC</arm_group_label>
    <arm_group_label>Crossover order ACB</arm_group_label>
    <arm_group_label>Crossover order BAC</arm_group_label>
    <arm_group_label>Crossover order BCA</arm_group_label>
    <arm_group_label>Crossover order CAB</arm_group_label>
    <arm_group_label>Crossover order CBA</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phytosterols + ezetimibe</intervention_name>
    <description>Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.</description>
    <arm_group_label>Crossover order ABC</arm_group_label>
    <arm_group_label>Crossover order ACB</arm_group_label>
    <arm_group_label>Crossover order BAC</arm_group_label>
    <arm_group_label>Crossover order BCA</arm_group_label>
    <arm_group_label>Crossover order CAB</arm_group_label>
    <arm_group_label>Crossover order CBA</arm_group_label>
    <other_name>A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Crossover order ABC</arm_group_label>
    <arm_group_label>Crossover order ACB</arm_group_label>
    <arm_group_label>Crossover order BAC</arm_group_label>
    <arm_group_label>Crossover order BCA</arm_group_label>
    <arm_group_label>Crossover order CAB</arm_group_label>
    <arm_group_label>Crossover order CBA</arm_group_label>
    <other_name>B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of any race or ethnicity between 18 to 80 years of age;

          -  Body mass index between 20 - 35 kg/m2;

          -  LDL-cholesterol between 130 - 189 mg/dL based on the average of duplicate screening
             measures. If the two LDL-C levels differ by more than 30 mg/dL, a third test will be
             scheduled with all three results averaged;

          -  Free of chronic disease;

          -  Willing to eat only the foods that are provided by the Center during the diet periods;

          -  Willing to abstain from the consumption of alcohol for 48-hours prior to blood draw
             days;

          -  Willing to drink no more than 5 cups of caffeine-containing beverages a day.

        Exclusion Criteria:

          -  Age &lt; 18 or &gt; 80 years;

          -  Based on duplicate screening laboratory values: 1)LDL-C &gt;=190 mg/dL; 2)TG &gt;=250
             mg/dL;3)blood pressure &gt;= 160 mm Hg systolic or 95 mm Hg diastolic;

          -  Documented presence of atherosclerotic disease;

          -  Diabetes mellitus;

          -  Renal, hepatic, endocrine, gastrointestinal, hematological or other systemic disease;

          -  Body mass index &gt; 35;

          -  For women, pregnancy, breast feeding or postpartum &lt; 6 months;

          -  For women, peri-menopausal;

          -  For women, sexually active but not practicing effective birth control methods;

          -  History of drug or alcohol abuse;

          -  History of depression or mental illness requiring treatment or medication within the
             last 6 months;

          -  multiple food allergies or significant food preferences or restrictions that would
             interfere with diet adherence;

          -  Chronic use of over-the-counter medication which would interfere with study endpoints
             including laxatives and antacids;

          -  Lifestyle or schedule incompatible with the study protocol;

          -  Planned continued use of dietary supplements through the study trial;

          -  Taking any lipid-lowering, or other medications known to affect blood cholesterol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Ostlund, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Advance Nutrition at Utah State University</name>
      <address>
        <city>Logan</city>
        <state>Utah</state>
        <zip>84322-4715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lin X, Racette SB, Lefevre M, Ma L, Spearie CA, Steger-May K, Ostlund RE Jr. Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans. Circulation. 2011 Aug 2;124(5):596-601. doi: 10.1161/CIRCULATIONAHA.110.006692. Epub 2011 Jul 18.</citation>
    <PMID>21768544</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 16, 2009</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <results_first_submitted>January 28, 2018</results_first_submitted>
  <results_first_submitted_qc>May 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2018</results_first_posted>
  <last_update_submitted>May 29, 2018</last_update_submitted>
  <last_update_submitted_qc>May 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phytosterols</keyword>
  <keyword>Ezetimibe</keyword>
  <keyword>Cholesterol Excretion</keyword>
  <keyword>Cholesterol Absorption</keyword>
  <keyword>Diet</keyword>
  <keyword>Mass Spectrometry</keyword>
  <keyword>Deuterium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>175 subjects were screened and 153 were excluded prior to randomization. 75 did not meet screening criteria, 39 declined to participate and 39 were not able to perform functions needed for the study. 22 Subjects were randomized and 21 completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Crossover Order ABC</title>
          <description>Subjects will undergo 3 periods of 21 days on a controlled diet plus phytosterols/placebo and ezetimibe/placebo. A washout of 7 days occurs between periods.
A. Phytosterols 2000 mg/day and ezetimibe 10 mg/day. B. Phytosterol placebo and ezetimibe placebo. C. Phytosterol placebo and active ezetimibe 10 mg/day. ezetimibe plus phytosterols.</description>
        </group>
        <group group_id="P2">
          <title>Crossover Order BCA</title>
          <description>Subjects will undergo 3 periods of 21 days on a controlled diet plus phytosterols/placebo and ezetimibe/placebo. A washout of 7 days occurs between periods.
A. Phytosterols 2000 mg/day and ezetimibe 10 mg/day. B. Phytosterol placebo and ezetimibe placebo. C. Phytosterol placebo and active ezetimibe 10 mg/day. ezetimibe plus phytosterols.</description>
        </group>
        <group group_id="P3">
          <title>Crossover Order BAC</title>
          <description>Subjects will undergo 3 periods of 21 days on a controlled diet plus phytosterols/placebo and ezetimibe/placebo. A washout of 7 days occurs between periods.
A. Phytosterols 2000 mg/day and ezetimibe 10 mg/day. B. Phytosterol placebo and ezetimibe placebo. C. Phytosterol placebo and active ezetimibe 10 mg/day. ezetimibe plus phytosterols.</description>
        </group>
        <group group_id="P4">
          <title>Crossover Order ACB</title>
          <description>Subjects will undergo 3 periods of 21 days on a controlled diet plus phytosterols/placebo and ezetimibe/placebo. A washout of 7 days occurs between periods.
A. Phytosterols 2000 mg/day and ezetimibe 10 mg/day. B. Phytosterol placebo and ezetimibe placebo. C. Phytosterol placebo and active ezetimibe 10 mg/day. ezetimibe plus phytosterols.</description>
        </group>
        <group group_id="P5">
          <title>Crossover Order CAB</title>
          <description>Subjects will undergo 3 periods of 21 days on a controlled diet plus phytosterols/placebo and ezetimibe/placebo. A washout of 7 days occurs between periods.
A. Phytosterols 2000 mg/day and ezetimibe 10 mg/day. B. Phytosterol placebo and ezetimibe placebo. C. Phytosterol placebo and active ezetimibe 10 mg/day. ezetimibe plus phytosterols.</description>
        </group>
        <group group_id="P6">
          <title>Crossover Order CBA</title>
          <description>Subjects will undergo 3 periods of 21 days on a controlled diet plus phytosterols/placebo and ezetimibe/placebo. A washout of 7 days occurs between periods.
A. Phytosterols 2000 mg/day and ezetimibe 10 mg/day. B. Phytosterol placebo and ezetimibe placebo. C. Phytosterol placebo and active ezetimibe 10 mg/day. ezetimibe plus phytosterols.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All study participants.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>race</title>
              <category_list>
                <category>
                  <title>white</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cholesterol Excretion</title>
        <description>Milligrams of fecal cholesterol and cholesterol metabolites excreted per day</description>
        <time_frame>At the end of week 3 on each diet</time_frame>
        <population>Healthy subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Phytosterol-Deficient Diet</title>
            <description>Phytosterol-deficient diet plus ezetimibe placebo plus phytosterol placebo.
Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols: Subjects will undergo three diet periods of 21 days each. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. Subjects will also receive either no active treatment, ezetimibe, or ezetimibe plus phytosterols.</description>
          </group>
          <group group_id="O2">
            <title>Diet Plus Ezetimibe</title>
            <description>Phytosterol-deficient diet plus 10 mg/day of ezetimibe plus phytosterol placebo.
Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols: Subjects will undergo three diet periods of 21 days each. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. Subjects will also receive either no active treatment, ezetimibe, or ezetimibe plus phytosterols.</description>
          </group>
          <group group_id="O3">
            <title>Diet Plus Ezetimibe Plus Phytosterols</title>
            <description>Phytosterol-deficient diet plus 10 mg/day of ezetimibe plus 2000 mg/day of phytosterols.
Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols: Subjects will undergo three diet periods of 21 days each. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. Subjects will also receive either no active treatment, ezetimibe, or ezetimibe plus phytosterols.</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol Excretion</title>
          <description>Milligrams of fecal cholesterol and cholesterol metabolites excreted per day</description>
          <population>Healthy subjects</population>
          <units>mg per day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505" lower_limit="386" upper_limit="625"/>
                    <measurement group_id="O2" value="794" lower_limit="615" upper_limit="973"/>
                    <measurement group_id="O3" value="962" lower_limit="757" upper_limit="1168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phytosterol Diet compared to Ezetimibe</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>289</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The estimation parameter is the difference between the placebo group and the ezetimibe group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo vs. Ezetimibe Plus Phytosterols</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The hypothesis is that groups are equal.</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>457</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ezetimibe vs. Ezetimibe Plus Phytosterols</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The hypothesis is that groups are equal</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>168</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Cholesterol Absorption</title>
        <description>Percent of intestinal cholesterol absorbed. Intestinal cholesterol is comprised of dietary cholesterol intake and endogenous cholesterol secreted into the intestinal lumen. Cholesterol absorption is the percent of intestinal cholesterol that is taken back up into the body and excluded from fecal excretion. It is also referred to as the efficiency of intestinal cholesterol absorption.</description>
        <time_frame>Determined on the final 5 days of each dietary period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phytosterol-Deficient Diet</title>
            <description>Phytosterol-deficient diet plus ezetimibe placebo plus phytosterol placebo</description>
          </group>
          <group group_id="O2">
            <title>Diet Plus Ezetimibe</title>
            <description>Phytosterol-deficient diet plus ezetimibe plus phytosterol placebo</description>
          </group>
          <group group_id="O3">
            <title>Diet Plus Ezetimibe Plus Phytosterols</title>
            <description>Phytosterol-deficient diet plus ezetimibe plus phytosterols</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Cholesterol Absorption</title>
          <description>Percent of intestinal cholesterol absorbed. Intestinal cholesterol is comprised of dietary cholesterol intake and endogenous cholesterol secreted into the intestinal lumen. Cholesterol absorption is the percent of intestinal cholesterol that is taken back up into the body and excluded from fecal excretion. It is also referred to as the efficiency of intestinal cholesterol absorption.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="61.8" upper_limit="76.2"/>
                    <measurement group_id="O2" value="46.2" lower_limit="38.5" upper_limit="53.9"/>
                    <measurement group_id="O3" value="32.6" lower_limit="26.9" upper_limit="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that groups are equal</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Not applicable in this study.</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Adjusted for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo vs. Ezetimibe Plus Phytosterols</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Adjusted for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>36.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that groups are equal.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Adjusted for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LDL Cholesterol</title>
        <time_frame>At the end of week 3 on each diet</time_frame>
        <population>Healthy subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Phytosterol-Deficient Diet</title>
            <description>Phytosterol-deficient diet plus ezetimibe placebo plus phytosterol placebo.</description>
          </group>
          <group group_id="O2">
            <title>Phytosterol-Deficient Diet Plus Ezetimibe</title>
            <description>Phytosterol-Deficient Diet Plus Ezetimibe Plus Phytosterol Placebo.</description>
          </group>
          <group group_id="O3">
            <title>Phytosterol-Deficient Diet Plus Ezetimibe Plus Phytosterols</title>
            <description>Phytosterol-deficient diet plus ezetimibe plus phytosterols.</description>
          </group>
        </group_list>
        <measure>
          <title>LDL Cholesterol</title>
          <population>Healthy subjects</population>
          <units>mg/deciliter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129" lower_limit="116" upper_limit="142"/>
                    <measurement group_id="O2" value="108" lower_limit="97" upper_limit="119"/>
                    <measurement group_id="O3" value="101" lower_limit="90" upper_limit="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that groups are equal.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that all groups are equal</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Adjusted for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that groups are equal.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Adjusted for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phytosterol-Deficient Diet</title>
          <description>Phytosterol-deficient diet plus ezetimibe placebo plus phytosterol placebo.
Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols: Subjects will undergo three diet periods of 21 days each. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. Subjects will also receive either no active treatment, ezetimibe, or ezetimibe plus phytosterols.</description>
        </group>
        <group group_id="E2">
          <title>Diet Plus Ezetimibe</title>
          <description>Phytosterol-deficient diet plus 10 mg/day of ezetimibe plus phytosterol placebo.
Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols: Subjects will undergo three diet periods of 21 days each. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. Subjects will also receive either no active treatment, ezetimibe, or ezetimibe plus phytosterols.</description>
        </group>
        <group group_id="E3">
          <title>Diet Plus Ezetimibe Plus Phytosterols</title>
          <description>Phytosterol-deficient diet plus 10 mg/day of ezetimibe plus 2000 mg/day of phytosterols.
Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols: Subjects will undergo three diet periods of 21 days each. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. Subjects will also receive either no active treatment, ezetimibe, or ezetimibe plus phytosterols.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard E. Ostlund MD</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-3516</phone>
      <email>rostlund@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

